Science & medicine news
-
Protein ‘anchor’ gives immunotherapy a boost
Relapsed cancer is challenging to treat. St. Jude scientists are studying how to use a chimeric antigen receptor (CAR) to target cancer cells, an approach that attracts immune cells that can destroy cancer.
-
St. Jude scientists create more efficient CAR immunotherapies using a molecular anchor
Discover how chimeric antigen receptors (CARs) with a new anchor domain increased anti-cancer activity of cellular immunotherapies in cancer models.
-
Thirumala-Devi Kanneganti, Ph.D. named 2022 AAAS Fellow
Immunologist recognized for her achievements in innate immunity, developing new concepts in inflammasome biology, inflammatory cell death.
-
Catherine Corbin named chief business innovation officer at St. Jude
Expert in human-centered design to lead new St. Jude department focused on advancing strategic plan.
-
St. Jude names leading researcher as new chair of oncology department
Julie R. Park, M.D., to succeed longtime chair Ching-Hon Pui, M.D.
-
Pioneering approach advances study of CTCF protein in transcription biology
Scientists at St. Jude used an innovative degradation system on CTCF, learning more about this protein’s role in transcription. Read about the findings.